What is Prostate Cancer?
Prostate cancer usually does not give rise to any symptoms till it is in advanced stages. Hence in many countries men over the age of fifty, who go for routine health check-ups are also advised to get checked for this cancer. A clinical test in the doctors surgery called digital rectal examination or DRE can pick up some of these cancers.
Prostate is a reproductive gland found in males and is an androgen (or testosterone) dependent sex gland that provides the bulk of seminal fluid during ejaculation. The prostatic fluid is excreted in the semen and helps nourish the sperms and keep it in the fluid state in the vagina.
Unlike other cancers the natural history of prostate cancer is different. Some prostate cancer are indolent and slow growing and may take years before they manifest or become sinister; whereas another group are more aggressive - like any other cancers and require urgent treatment.
If the cancer is picked up during a routine periodic check, a biopsy of the gland is advised to determine the aggressiveness of the tumour. The decision on how to treat the cancer is usually a decision that is taken by the treating Urologist. He determines by various tests the stage of the disease and decides on the line of treatment that is suitable for the patient.
If the cancer is still in its early stages and the patient is relatively young and in good health, they are usually advised to undergo a ‘Radical Prostatectomy'. However if the patient has early disease but is in poor health - hormonal manipulation and radiotherapy may be a better option to avoid the risks of surgery.
Over the last couple of decades much research involving the prostate cancer has taken place and the disease is better understood. We however still have not been able to answer the question about which cancers requires urgent treatment and which do not require treatment. The research in genetics and proteomics may help us answer this important question in the near future.
Latest Publication and Research on Prostate CancerOncomir miR-125b Suppresses p14(ARF) to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer. - Published by PubMed
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. - Published by PubMed
Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1. - Published by PubMed
Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. - Published by PubMed
Indole-3-carbinol and 3', 3'-diindolylmethane modulate androgen's effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells. - Published by PubMed